CD4 and rosacea: Previous studies have demonstrated that in an LL-37-induced rosacea-like mouse model, topical application of tofacitinib significantly improved rosacea-like phenotypes, reduced CD4+ T cell and mast cell infiltration, and suppressed dermal angiogenesis.